Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 2
1996 3
1997 1
1999 1
2002 1
2004 1
2005 2
2007 1
2009 2
2011 1
2014 2
2015 1
2016 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E, Rosenwald A, Berger F, Bernd HW, Hartmann S, Loddenkemper C, Barth TF, Brousse N, Pileri S, Rymkiewicz G, Kodet R, Stilgenbauer S, Forstpointner R, Thieblemont C, Hallek M, Coiffier B, Vehling-Kaiser U, Bouabdallah R, Kanz L, Pfreundschuh M, Schmidt C, Ribrag V, Hiddemann W, Unterhalt M, Kluin-Nelemans JC, Hermine O, Dreyling MH, Klapper W. Hoster E, et al. J Clin Oncol. 2016 Apr 20;34(12):1386-94. doi: 10.1200/JCO.2015.63.8387. Epub 2016 Feb 29. J Clin Oncol. 2016. PMID: 26926679
The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict the clinical heterogeneity. ...We evaluated prognostic effects for overall survival (OS) by Cox regression. For …
The Ki-67 index is a strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which d …
[Monoclonal antibody treatment of malignant lymphoma].
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Internist (Berl). 2004 Dec;45(12):1370-7. doi: 10.1007/s00108-004-1299-z. Internist (Berl). 2004. PMID: 15517123 Review. German.
In the last years monoclonal antibodies directed against B-cell associated epitopes have enriched our armentarium of therapeutic strategies against malignant B-cell lymphoma. ...
In the last years monoclonal antibodies directed against B-cell associated epitopes have enriched our armentarium of therapeutic stra …
Current management of mantle cell lymphoma.
Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Weigert O, et al. Drugs. 2007;67(12):1689-702. doi: 10.2165/00003495-200767120-00004. Drugs. 2007. PMID: 17683170 Review.
Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. ...
Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this …
Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M. Hagenbeek A, et al. Anticancer Drugs. 2002 Nov;13 Suppl 2:S11-7. Anticancer Drugs. 2002. PMID: 12710586 Review.
Rituximab is a specific anti-CD20 chimeric monoclonal antibody against the CD20 antigen, which is stably expressed on most B-cells (from the pre-B-cell stage). Compared with chemotherapy, rituximab has an excellent tolerability profile, making it a good therapeutic …
Rituximab is a specific anti-CD20 chimeric monoclonal antibody against the CD20 antigen, which is stably expressed on most B-cells (f …
Mantle cell lymphoma: state-of-the-art management and future perspective.
Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Weigert O, et al. Leuk Lymphoma. 2009 Dec;50(12):1937-50. doi: 10.3109/10428190903288514. Leuk Lymphoma. 2009. PMID: 19863180 Review.
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression. ...
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphomas (NHL) characterized in almost all cases by the chromos …
[Monoclonal antibody therapy for malignant lymphoma].
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Med Klin (Munich). 2005 Jan 15;100(1):14-24. doi: 10.1007/s00063-005-1115-0. Med Klin (Munich). 2005. PMID: 15654538 Review. German.
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific monoclonal antibodies. One of the reasons for the attractiveness of this approach is the different mode of action of these antibodies compared …
The treatment options for patients with malignant lymphoma have been substantially enriched by the development of B-cell-specific mon …
Transplantation strategies for patients with follicular lymphoma.
Buske C, Dreyling M, Unterhalt M, Hiddemann W. Buske C, et al. Curr Opin Hematol. 2005 Jul;12(4):266-72. doi: 10.1097/01.moh.0000166499.72138.57. Curr Opin Hematol. 2005. PMID: 15928482 Review.
PURPOSE OF REVIEW: This review summarizes the current status and new developments in autologous and allogeneic transplantation strategies for patients with follicular lymphoma including novel concepts of myeloablative radioimmunotherapy, allogeneic transplantation with dose-reduc …
PURPOSE OF REVIEW: This review summarizes the current status and new developments in autologous and allogeneic transplantation strategies fo …
Skin Involvement of Mantle Cell Lymphoma May Mimic Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type.
Wehkamp U, Pott C, Unterhalt M, Koch K, Weichenthal M, Klapper W, Oschlies I. Wehkamp U, et al. Am J Surg Pathol. 2015 Aug;39(8):1093-101. doi: 10.1097/PAS.0000000000000445. Am J Surg Pathol. 2015. PMID: 26034867
Mantle cell lymphoma (MCL) is a B-cell neoplasm with a variable and generally aggressive clinical course. ...Lymphomas with these features might be erroneously diagnosed as diffuse large B-cell lymphoma, leg type, if cyclin D1 staining is not performed....
Mantle cell lymphoma (MCL) is a B-cell neoplasm with a variable and generally aggressive clinical course. ...Lymphomas with these fea …
Current status and future perspectives in the treatment of low-grade non-Hodgkin's lymphomas.
Hiddemann W, Unterhalt M. Hiddemann W, et al. Blood Rev. 1994 Dec;8(4):225-33. doi: 10.1016/0268-960x(94)90110-4. Blood Rev. 1994. PMID: 7888829 Review.
The currently available information justifies a conservative approach of observing the natural course of the disease until therapeutic intervention is required due to the occurrence of B-symptoms, hematopoietic insufficiency or lymphoma progression....
The currently available information justifies a conservative approach of observing the natural course of the disease until therapeutic inter …
21 results